Our study showed that patients with high NAT CBX8 were associated with a worse stage, tumor invasion, lymph node metastasis, distant metastasis, and poor DFS and OS, suggesting that CRC patients with high NAT CBX8 are potential candidates for CBX8-targeted treatment. The gene discussed is BRD2; the disease is metastatic malignant neoplasm in the lymph nodes.